Twenty-five of the 2014 novel new drugs were designated Priority Review, in which the FDA determined the drug to potentially provide a significant advance in medical care.
Twenty-five of the 2014 novel new drugs were designated Priority Review, in which the FDA determined the drug to potentially provide a significant advance in medical care.
